Publications & posters

Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.

Filter

Jul 2020 | FROM AKERO THERAPEUTICS

AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients

Kaufman, A. et al. Cell Reports Medicine

Dec 2019 | FROM EXTERNAL EXPERTS

Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial

Sanyal, A. et al. Lancet

Aug 2018 | FROM EXTERNAL EXPERTS

A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway

Bao, L. et al. British Journal of Pharmacology

Jul 2018 | FROM EXTERNAL EXPERTS

A systematic dissection of sequence elements determining β-Klotho and FGF interaction and signaling

Shi, S.Y. et al. Scientific Reports

Jul 2018 | From External Experts

FGF21 gene therapy as treatment for obesity and insulin resistance

Jimenez, V., et al EMBO Molecular Medicine

Jun 2018 | FROM EXTERNAL EXPERTS

Recent advances in understanding and managing non-alcoholic fatty liver disease

Albhaisa, S., Sanyal A. F1000 Research

Feb 2018 | From External Experts

LY2405319, an analog of fibroblast growth factor 21 ameliorates α-smooth muscle actin production through inhibition of the succinate—G-protein couple receptor 91 (GPR91) pathway in mice

Le, C.T., et al PLoS One

Jan 2018 | From External Experts

Structures of β-klotho reveal a ‘zip code’-like mechanism for endocrine FGF signalling

Lee, S., et al Nature

We are evaluating potential treatments for NASH and other serious metabolic diseases to build our pipeline.

View Our Pipeline

We are evaluating potential treatments for NASH and other serious metabolic diseases to build our pipeline.

View Our Pipeline